IMCR — Immunocore Holdings Share News
0.000.00%
Last trade - 00:00- $1.54bn
- $1.05bn
- $400.02m
Brief: Immunocore Holdings Says Early On-Treatment ctDNA Reduction In Stable Disease Patients Treated With KIMMTRAK Was Associated With Longer Overall Survival
Brief: Immunocore Reports Q1 2023 Financial Results And Provides Business Update
Brief: Immunocore Presents New Data Confirming Association Between Early Ctdna Reduction & Longer Overall Survival
Brief: Grey Wolf Therapeutics Reports Promising Preclinical Data From Research Collaboration With Immunocore
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
Brief: Immunocore Reports 2022 Financial Results And Provides Business Update
Immunocore Holdings PLC reports results for the quarter ended in December - Earnings Summary
Immunocore Holdings PLC expected to post breakeven results a share - Earnings Preview
Brief: Immunocore Announces Data With First Soluble Tcr Therapy For People Living With Hiv
Brief: Immunocore Presents Ovarian Cancer Expansion Data For ImmTAC Candidate IMC-C103C Targeting MAGE-A4
Brief: Immunocore And Gadeta Announce Agreement To Develop First Gamma Delta (Γδ) Tcr Immtac For Solid Tumors
Barclays initiates Immunocore at 'overweight' on cancer pipeline prospects
Brief: Immunocore Presents New Biomarker Analysis For Kimmtrak
Brief: Immunocore Reports Third Quarter 2022 Financial Results
Entered Into Open Market Sale Agreement With Jefferies Llc
Immunocore climbs on upbeat sales of eye cancer drug
Immunocore Holdings PLC reports results for the quarter ended in June - Earnings Summary
Brief: Immunocore Reports Q2 Results, Provides Business Update
Immunocore Holdings PLC expected to post a loss of 67 pence a share - Earnings Preview